Medexus Pharmaceuticals (TSE:MDP) Given a C$8.25 Price Target at Leede Financial

Leede Financial set a C$8.25 price objective on Medexus Pharmaceuticals (TSE:MDP) in a report released on Monday, Marketbeat reports. The firm currently has a speculative buy rating on the stock. Leede Financial also issued estimates for Medexus Pharmaceuticals’ Q2 2025 earnings at $0.11 EPS, Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.03 EPS, FY2025 earnings at $0.34 EPS, Q1 2026 earnings at $0.10 EPS, Q2 2026 earnings at $0.03 EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.07 EPS, FY2026 earnings at $0.23 EPS, Q1 2027 earnings at $0.11 EPS, Q2 2027 earnings at $0.12 EPS, FY2027 earnings at $0.56 EPS and FY2028 earnings at $0.79 EPS.

A number of other equities research analysts have also commented on MDP. Stifel Nicolaus raised their price objective on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a buy rating in a report on Thursday, August 22nd. Stifel Canada upgraded Medexus Pharmaceuticals from a moderate buy rating to a strong-buy rating in a report on Monday, August 12th. Finally, Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a strong-buy rating in a report on Wednesday, June 26th. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of Buy and a consensus target price of C$5.25.

Medexus Pharmaceuticals Trading Down 0.4 %

MDP stock opened at C$2.57 on Monday. Medexus Pharmaceuticals has a 1-year low of C$1.44 and a 1-year high of C$3.36. The business’s 50-day moving average price is C$2.46 and its two-hundred day moving average price is C$2.00. The firm has a market cap of C$63.04 million, a PE ratio of 51.60 and a beta of 1.95.

Medexus Pharmaceuticals (TSE:MDP) last issued its quarterly earnings data on Wednesday, August 7th. The company reported C$0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of C$0.04 by C$0.07. The business had revenue of C$37.33 million during the quarter, compared to analyst estimates of C$36.95 million. Medexus Pharmaceuticals had a return on equity of 3.95% and a net margin of 1.00%. On average, analysts forecast that Medexus Pharmaceuticals will post 0.1626066 earnings per share for the current year.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.